Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03675022 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis
A Early Phase 1 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT03675022: Clinical Trial Early Phase 1 study, sponsored by Brigham and Women's Hospital.
NCT03675022 is a Early Phase 1 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 9 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03675022, a Early Phase 1 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Obstructive Sleep Apnea (OSA) is a common disorder with serious consequences that remains underrecognized, with \>80% of OSA patients undiagnosed, and undertreated due to inadequate treatment options. The development of additional treatments for OSA, such as pharmacotherapy, are critically needed. The collaboration between Regeneron and Sanofi are funding this project. Regeneron will be providing the drug and the contract will be with Regeneron. Both companies are involved as it is a collaboration across the companies.
Primary Outcome
The effect of dupilumab on OSA severity in patients with nasal obstruction due to chronic rhinosinusitis with or without nasal polyposis (Bilateral CRS). AHI is the amount of respiratory events that a patient has per hours of sleep.
Interventions
- DRUG Dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-08-15 |
| Est. Completion | 2022-07-01 |
| Phase | Early Phase 1 |
Why NCT03675022 stopped before completion
NCT03675022 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Dupilumab is the first listed.
NCT03675022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03675022 about?
NCT03675022 is a clinical study titled "Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis". Obstructive Sleep Apnea (OSA) is a common disorder with serious consequences that remains underrecognized, with \>80% of OSA patients undiagnosed, and undertreated due to inadequate treatment options. The development of additional treatments for OSA, such as pharmacotherapy, are critically needed. ...
What is the current status of trial NCT03675022?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2018-08-15. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT03675022?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03675022?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03675022's enrollment target sits among peer trials
9 1745th of 2000 higher than 219 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI